$82
0.12%
Downside
Day's Volatility :3.88%
Upside
3.77%
19.04%
Downside
52 Weeks Volatility :29.78%
Upside
13.27%
Period | Ge Healthcare Technologies Inc. | Index (NASDAQ Composite) |
---|---|---|
3 Months | 0.5% | 5.8% |
6 Months | 3.61% | 12.7% |
1 Year | 15.7% | 33.6% |
3 Years | 40.35% | 18.1% |
Market Capitalization | 37.7B |
Book Value | $18.20 |
Dividend Share | 0.12 |
Dividend Yield | 0.15% |
Earnings Per Share (EPS) | 3.65 |
PE Ratio | 22.61 |
PEG Ratio | 2.06 |
Wall Street Target Price | 96.966 |
Profit Margin | 8.56% |
Operating Margin TTM | 16.06% |
Return On Assets TTM | 5.64% |
Return On Equity TTM | 21.85% |
Revenue TTM | 19.6B |
Revenue Per Share TTM | 42.92 |
Quarterly Revenue Growth YOY | 0.8999999999999999% |
Gross Profit TTM | 7.2B |
EBITDA | 3.6B |
Diluted Eps TTM | 3.65 |
Quarterly Earnings Growth YOY | 0.24 |
EPS Estimate Current Year | 4.28 |
EPS Estimate Next Year | 4.68 |
EPS Estimate Current Quarter | 1.05 |
EPS Estimate Next Quarter | 1.3 |
What analysts predicted
Upside of 18.25%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 16.6B | - |
Net Income | 1.5B | - |
Net Profit Margin | 9.16% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 17.2B | ↑ 3.19% |
Net Income | 2.1B | ↑ 35.04% |
Net Profit Margin | 11.99% | ↑ 2.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 17.6B | ↑ 2.45% |
Net Income | 2.2B | ↑ 9.18% |
Net Profit Margin | 12.78% | ↑ 0.79% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 18.3B | ↑ 4.3% |
Net Income | 1.9B | ↓ 14.73% |
Net Profit Margin | 10.45% | ↓ 2.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 19.6B | ↑ 6.6% |
Net Income | 3.1B | ↑ 62.0% |
Net Profit Margin | 15.88% | ↑ 5.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 2.34% |
Net Income | 418.0M | ↑ 12.37% |
Net Profit Margin | 8.68% | ↑ 0.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 0.1% |
Net Income | 375.0M | ↓ 10.29% |
Net Profit Margin | 7.78% | ↓ 0.9% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.2B | ↑ 7.96% |
Net Income | 403.0M | ↑ 7.47% |
Net Profit Margin | 7.74% | ↓ 0.04% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.7B | ↓ 10.68% |
Net Income | 374.0M | ↓ 7.2% |
Net Profit Margin | 8.04% | ↑ 0.3% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 4.06% |
Net Income | 428.0M | ↑ 14.44% |
Net Profit Margin | 8.84% | ↑ 0.8% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.9B | ↑ 0.5% |
Net Income | 471.0M | ↑ 10.05% |
Net Profit Margin | 9.69% | ↑ 0.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 24.2B | - |
Total Liabilities | 9.5B | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 26.3B | ↑ 8.59% |
Total Liabilities | 9.6B | ↑ 1.64% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 27.5B | ↑ 4.68% |
Total Liabilities | 18.2B | ↑ 88.71% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 32.5B | ↑ 17.85% |
Total Liabilities | 25.1B | ↑ 38.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.3B | ↓ 1.0% |
Total Liabilities | 25.0B | ↓ 3.67% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.4B | ↑ 0.22% |
Total Liabilities | 25.2B | ↑ 1.01% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.5B | ↑ 0.22% |
Total Liabilities | 25.1B | ↓ 0.38% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 32.2B | ↓ 0.76% |
Total Liabilities | 24.6B | ↓ 2.13% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 31.9B | ↓ 1.11% |
Total Liabilities | 23.9B | ↓ 3.06% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 33.9B | ↑ 6.29% |
Total Liabilities | 25.3B | ↑ 6.23% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | - |
Investing Cash Flow | -325.0M | - |
Financing Cash Flow | -1.6B | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↓ 15.18% |
Investing Cash Flow | -323.0M | ↓ 0.62% |
Financing Cash Flow | -21.5B | ↑ 1268.74% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↓ 4.74% |
Investing Cash Flow | -1.8B | ↑ 445.2% |
Financing Cash Flow | -263.0M | ↓ 98.78% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 31.49% |
Investing Cash Flow | -398.0M | ↓ 77.4% |
Financing Cash Flow | -822.0M | ↑ 212.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -67.0M | ↓ 114.32% |
Investing Cash Flow | -84.0M | ↓ 68.42% |
Financing Cash Flow | -227.0M | ↓ 133.73% |
Sell
Neutral
Buy
Ge Healthcare Technologies Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ge Healthcare Technologies Inc. | -5.46% | 3.61% | 15.7% | 40.35% | 40.35% |
Solventum Corp | -6.44% | 11.71% | -1.03% | -1.03% | -1.03% |
Doximity, Inc. | 18.95% | 77.2% | 107.57% | -15.51% | -5.85% |
Veeva Systems Inc. | -5.08% | 0.66% | 19.4% | -27.88% | 39.8% |
Healthequity Inc | 17.35% | 29.82% | 52.58% | 69.45% | 67.8% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ge Healthcare Technologies Inc. | 22.66 | 22.61 | 2.06 | 4.28 | 0.22 | 0.06 | 0.0 | 18.2 |
Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
Doximity, Inc. | 60.01 | 59.23 | 2.42 | 0.9 | 0.19 | 0.12 | NA | 5.15 |
Veeva Systems Inc. | 56.83 | 55.82 | 1.23 | 4.76 | 0.13 | 0.06 | NA | 32.04 |
Healthequity Inc | 85.33 | 85.56 | 1.11 | 2.19 | 0.05 | 0.03 | NA | 24.7 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ge Healthcare Technologies Inc. | Buy | $37.8B | 40.35% | 22.66 | 8.56% |
Solventum Corp | Hold | $10.8B | -1.03% | NA | 15.73% |
Doximity, Inc. | Hold | $9.2B | -5.85% | 60.01 | 33.69% |
Veeva Systems Inc. | Buy | $34.6B | 39.8% | 56.83 | 23.91% |
Healthequity Inc | Buy | $8.9B | 67.8% | 85.33 | 9.61% |
Insights on Ge Healthcare Technologies Inc.
Revenue is up for the last 3 quarters, 4.65B → 4.86B (in $), with an average increase of 2.2% per quarter
Netprofit is up for the last 3 quarters, 374.0M → 471.0M (in $), with an average increase of 10.9% per quarter
In the last 1 year, Doximity, Inc. has given 107.6% return, outperforming this stock by 91.9%
In the quarter ending March,2024. Ge Healthcare Technologies Inc. has declared dividend of $0.03
Read Morege healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i
Organization | Ge Healthcare Technologies Inc. |
Employees | 51000 |
CEO | Mr. Peter J. Arduini |
Industry | Healthcare |